Business Context and Reporting Period
Company: Bruker Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: Bruker designs, manufactures, and services life science and materials research systems based on core technologies including X-ray, magnetic resonance, mass spectrometry, and optical emission spectroscopy. The company also produces superconducting wire products and field analytical systems for CBRN detection. Operations are organized into two reporting segments: Scientific Instruments and Energy and Supercon Technologies.
Key Financial Metrics
| Metric (in millions) | Q2 2009 | Q2 2008 | YTD 6mo 2009 | YTD 6mo 2008 |
|---|---|---|---|---|
| Total Revenue | $252.5 | $311.5 | $483.0 | $549.8 |
| Gross Profit | $111.2 | $129.6 | $213.9 | $243.6 |
| Gross Margin % | 44.0% | 41.6% | 44.3% | 44.3% |
| Operating Income | $20.2 | $28.4 | $34.5 | $44.2 |
| Operating Margin % | 8.0% | 9.1% | 7.1% | 8.0% |
| Net Income (Attributable to Bruker) | $12.9 | $21.7 | $21.3 | $20.9 |
| Diluted EPS | $0.08 | $0.13 | $0.13 | $0.13 |
| Cash from Operations (YTD) | $51.3 | $18.1 | ||
| Cash & Equivalents (End of Period) | ||||
| Total Debt (Outstanding) | $170.7 | $223.8 |
Material Changes vs. Prior Period
- Revenue Decline: Q2 2009 revenue decreased 18.9% year-over-year. Approximately $24.4 million of the decline was due to foreign exchange impacts (strengthening USD). Organic revenue decreased 11.1%, driven by lower sales of magnetic resonance and X-ray systems, partially offset by higher mass spectrometry volumes.
- Margin Expansion: Despite lower revenue, gross margins improved to 44.0% in Q2 2009 from 41.6% in Q2 2008. This was attributed to favorable product mix (higher-margin mass spectrometry), productivity improvements, and cost-cutting initiatives.
- Operating Expenses: Total operating expenses decreased to $91.0 million in Q2 2009 from $101.2 million in Q2 2008, primarily due to foreign exchange benefits and cost savings programs.
- Acquisition Activity: In April 2009, the company acquired the research instruments business of ACCEL Instruments GmbH for approximately $0.4 million, resulting in a $2.1 million bargain purchase gain recorded in the Energy and Supercon Technologies segment.
- Debt Reduction: Total outstanding debt decreased from $223.8 million at year-end 2008 to $170.7 million at June 30, 2009, following net repayments of approximately $51.7 million in the first half of 2009.
Outlook, Risks, and Unusual Items
- Market Conditions: Management attributes reduced sales to industrial customers to the worldwide recession. Conversely, demand from academic and government customers has increased due to stimulus packages in the U.S., Germany, and Japan.
- Unusual Items:
- Impairment Charge: A $0.7 million impairment charge was recorded in Q2 2009 for fixed assets used in superconducting wire production.
- Restructuring: Additional restructuring charges of $0.3 million were recorded in Q2 2009 related to a severance program in the Netherlands.
- Foreign Exchange: The company recorded net gains of $0.6 million on foreign currency transactions for the six months ended June 30, 2009, compared to net losses of $9.0 million in the prior year period.
- Risks and Contingencies:
- Legal Proceedings: A civil action regarding a former employee's Sarbanes-Oxley claim was settled in June 2009 for a non-material amount. A contractual dispute with Agilent Technologies regarding intellectual property remains unresolved following failed mediation.
- Tax Audits: German subsidiaries are under audit for tax years 2003–2008, and a Swiss entity is under audit for 2003–2006. The company cannot predict the timing or outcome.
- Liquidity: The company maintains a credit agreement with $230 million in revolving commitments and $150 million in term loans. As of June 30, 2009, $206.3 million was available under the Credit Agreement.
Investor Verification Checklist
- Revenue Mix: Verify the sustainability of the shift in demand from industrial to academic/government sectors and the impact of government stimulus packages on future orders.
- Foreign Exchange Sensitivity: Assess the company's hedging strategies given the significant impact of USD strength on reported revenue and operating income.
- Debt Covenants: Confirm continued compliance with leverage and interest coverage ratios under the Credit Agreement, especially given the reduction in operating income.
- Legal Exposure: Monitor the status of the Agilent Technologies dispute and the outcome of ongoing tax audits in Germany and Switzerland.
- Inventory Levels: Review the $436.4 million inventory balance, specifically the $85.2 million in inventory-in-transit, to ensure no significant write-downs are required due to delayed customer acceptances.